The U.S. Food and Drug Administration has approved Sanofi's Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce ...

In light of two high-profile NBA stars suffering from blood clots, we asked doctors how they happen and if they are occurring ...

Swedish Orphan Biovitrum, the Nordic biotech also known as Sobi, has announced that the National Institute for Health and ...

Sanofi's Qfitlia gains FDA approval, offering fewer injections in hemophilia care. Check out my recommendation for SNY stock.

The FDA approves Sanofi's Qfitlia as the first therapy in the United States to treat hemophilia A or B with or without ...

Researchers said a better understanding of barriers to bone health in hemophilia and VWD is needed, and guidelines should be ...

Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.

The findings showed that fitusiran lowers antithrombin levels to enhance thrombin generation and restore hemostasis in ...

The FDA has approved fitusiran, now Qfitlia, as a treatment for hemophilia A or B patients, ages 12 and older, with or ...

Qfitlia is the first FDA-approved antithrombin-lowering therapy indicated for routine prophylaxis to prevent or reduce ...

FDA approves Sanofi's Qfitlia, the first antithrombin-lowering therapy for hemophilia A or B, reducing bleeding episodes with ...